Two Sigma Investments LP Buys 12,154 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Two Sigma Investments LP raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 54.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 34,543 shares of the biopharmaceutical company's stock after acquiring an additional 12,154 shares during the period. Two Sigma Investments LP's holdings in Regeneron Pharmaceuticals were worth $24,606,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of REGN. Rakuten Securities Inc. grew its position in shares of Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 15 shares in the last quarter. OFI Invest Asset Management purchased a new position in Regeneron Pharmaceuticals during the 4th quarter valued at approximately $28,000. Avalon Trust Co bought a new stake in Regeneron Pharmaceuticals in the 4th quarter worth approximately $36,000. Crowley Wealth Management Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $36,000. Finally, Private Wealth Management Group LLC raised its holdings in shares of Regeneron Pharmaceuticals by 260.0% during the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock worth $38,000 after acquiring an additional 39 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on REGN. UBS Group cut their target price on shares of Regeneron Pharmaceuticals from $768.00 to $633.00 and set a "neutral" rating for the company in a report on Wednesday, April 30th. Leerink Partners raised shares of Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and lifted their price objective for the stock from $762.00 to $834.00 in a research note on Wednesday, February 5th. Canaccord Genuity Group upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, April 22nd. Royal Bank of Canada lowered their price target on shares of Regeneron Pharmaceuticals from $1,051.00 to $943.00 and set an "outperform" rating for the company in a report on Wednesday, April 30th. Finally, The Goldman Sachs Group dropped their price target on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, four have given a hold rating, nineteen have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $890.60.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $604.62 on Thursday. The stock has a market capitalization of $65.28 billion, a PE ratio of 15.79, a PEG ratio of 2.34 and a beta of 0.43. The company has a 50 day moving average price of $595.54 and a 200-day moving average price of $679.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $520.50 and a fifty-two week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.03 billion for the quarter, compared to analysts' expectations of $3.40 billion. During the same quarter in the prior year, the company earned $9.55 EPS. The firm's quarterly revenue was down 3.7% on a year-over-year basis. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.58%. The ex-dividend date of this dividend is Tuesday, May 20th. Regeneron Pharmaceuticals's payout ratio is currently 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.